IP Library Granted Patent US 7,326,533
Granted Patent B2
US 7,326,533 · App. 11/495,262 · Granted Feb 5, 2008

Detection rpoB sequences of

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,326,533
App. No.
11/495,262
Granted
Feb 5, 2008
Kind
B2
Abstract

A method of detecting rpoB sequences of Mycobacterium tuberculosis present in a biological sample that includes steps of amplifying the M. tuberculosis rpoB sequence in vitro in a nucleic acid amplification mixture that includes specific disclosed primer sequences, and detecting the amplified sequences by using probes that provide information by their specific hybridization to portions of the amplified nucleic acid is disclosed. Compositions for amplifying and detecting in vitro the rpoB sequences of M. tuberculosis in a sample are disclosed.

Claims (15)

1. A method of detecting rpoB sequences of Mycobacterium tuberculosis present in a biological sample, comprising the steps of: providing a biological sample containing nucleic acid from M. tuberculosis comprising a rpoB sequence; amplifying the rpoB sequence in an in vitro nucleic acid amplification reaction mixture comprising at least one polymerase activity, and a first primer consisting of SEQ ID NO: 2 and a second primer consisting of SEQ ID NO: 8 to produce amplified nucleic acid containing a rpoB sequence; optionally fragmenting the amplified nucleic acid; hybridizing the amplified nucleic acid to at least one detection probe consisting of SEQ ID NO:4 that hybridizes specifically to M. tuberculosis sequences; and detecting the amplified nucleic acid hybridized to at least one detection probe by detecting a label associated with the amplified nucleic acid, thereby detecting the rpoB sequences of Mycobacterium tuberculosis present in the biological sample.

2. The method of claim 1 , before the amplifying step, further comprising the steps of: adding to the biological sample a combination of first and second capture oligomers consisting of SEQ ID NO: 5 and SEQ ID NO: 6 wherein the first and second capture oligomers specifically hybridize to a M. tuberculosis sequence specific for each capture oligomer, and an immobilized nucleic acid that hybridizes to a 3′ tail sequence of the first and second capture oligomers; hybridizing the nucleic acid from M. tuberculosis , the capture oligomers, and the immobilized nucleic acids to produce a hybridization complex comprising the nucleic acid from M. tuberculosis, at least one of the first and second capture oligomers, and the immobilized nucleic acid; and separating the hybridization complex from other components of the biological sample.

3. The method of claim 1 , wherein the amplifying step uses a helper oligomer consisting of SEQ ID NO: 1.

4. The method of claim 1 , wherein amplifying comprises transcription-mediated amplification.

5. The method of claim 1 , wherein amplifying comprises polymerase chain reaction (PCR) amplification.

6. The method of claim 1 , wherein the method includes chemically fragmenting the amplified nucleic acid and fluorescently labeling fragments of the amplified nucleic acid.

7. A composition for detecting a rpoB sequence of M. tuberculosis , comprising an oligonucleotide consisting of SEQ ID NO: 2, an oligonucleotide consisting of SEQ ID NO 8, and optionally at least one detection probe consisting of SEQ ID NO: 4.

8. The composition of claim 7 , further comprising an oligonucleotide consisting of SEQ ID NO: 1.

9. The composition of claim 7 , further comprising a combination of a first oligonucleotide consisting of SEQ ID NO: 5 and a second oligonucleotide consisting of SEQ ID NO: 6.

10. A kit comprising: an oligonucleotide consisting of SEQ ID NO: 2, an oligonucleotide consisting of SEQ ID NO: 8, and at least one oligonucleotide selected from the group consisting of an oligonucleotide consisting of SEQ ID NO: 1 and an oligonucleotide consisting of SEQ ID NO: 4.

11. The kit of claim 10 , comprising the oligonucleotide consisting of SEQ ID NO: 1.

12. The kit of claim 10 , comprising the oligonucleotide consisting of SEQ ID NO: 4.

13. The kit of claim 10 , further comprising an oligonucleotide consisting of SEQ ID NO: 5 and an oligonucleotide consisting of SEQ ID NO: 6.

14. The kit of claim 10 , further comprising an oligonucleotide consisting of SEQ ID NO: 10 or an oligonucleotide consisting of SEQ ID NO: 11.

15. The kit of claim 10 , comprising an oligonucleotide consisting of SEQ ID NO: 1 and an oligonucleotide consisting of SEQ ID NO: 4.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →